1782350-51-9

Usage

Uses

Used in Pharmaceutical Research:
(3R,4R)-1-(tert-butoxycarbonyl)pyrrolidine-3,4-dicarboxylic acid is used as a chiral building block for the development of pharmaceuticals and biologically active molecules. Its unique structure and stereochemistry allow for the creation of enantiopure compounds, which are essential in the pharmaceutical industry for producing effective and safe drugs.
Used in Organic Synthesis:
In the field of organic synthesis, (3R,4R)-1-(tert-butoxycarbonyl)pyrrolidine-3,4-dicarboxylic acid serves as a key intermediate for the synthesis of complex organic molecules. Its Boc protecting group facilitates the synthesis of peptides and the protection of amine groups, making it a valuable asset in the development of new chemical compounds.
Used in Academia:
(3R,4R)-1-(tert-butoxycarbonyl)pyrrolidine-3,4-dicarboxylic acid is also utilized in academic research, where it contributes to the advancement of knowledge in the fields of chemistry and biology. Its unique properties and potential applications make it an attractive subject for study and experimentation, further expanding the understanding of its capabilities and potential uses.
Used in Industry:
(3R,4R)-1-(tert-butoxycarbonyl)pyrrolidine-3,4-dicarboxylic acid (3R,4R)-1-(tert-butoxycarbonyl)pyrrolidine-3,4-dicarboxylic acid is employed in the chemical and pharmaceutical industries for the large-scale production of various compounds and drugs. Its versatility and potential applications make it a valuable resource for the development of new products and technologies.

Upstream product

• 595547-21-0 ethyl (3S,4S)-N-Boc-pyrrolidine-3,4-dicarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 111186-67-5 dimethyl trans-1-benzylpyrrolidine-3,4-dicarboxylate 
• 102389-88-8 dimethyl pyrrolidine-3,4-dicarboxylate 
• 87813-05-6 dimethyl (3R,4R)-1-benzylpyrrolidine-3,4-dicarboxylate 
• 92486-65-2 diethyl trans-N-benzyl-pyrrolidine-3,4-dicarboxylate 

Relevant academic research and scientific papers

TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

The present disclosure relates to compounds which modulate the activity of Toll-like receptor (TLR) proteins, including agonists or activators, partial agonists, and antagonists. Of particular interest of compounds that modulate the activity of TLR2, as well as methods of using such compounds to treat cancer and other disorders associated with a TLR2 pathway.

Mechanism-Inspired Design of Bifunctional Catalysts for the Alternating Ring-Opening Copolymerization of Epoxides and Cyclic Anhydrides

Advances in catalysis have enabled the ring-opening copolymerization of epoxides and cyclic anhydrides to afford structurally and functionally diverse polyesters with controlled molecular weights and dispersities. However, the most common systems employ b

Diprovocims: A New and Exceptionally Potent Class of Toll-like Receptor Agonists

A screen conducted with nearly 100000 compounds and a surrogate functional assay for stimulation of an immune response that measured the release of TNF-α from treated human THP-1 myeloid cells differentiated along the macrophage line led to the discovery of the diprovocims. Unique to these efforts and of special interest, the screening leads for this new class of activators of an immune response came from a compound library designed to promote cell-surface receptor dimerization. Subsequent comprehensive structure-activity relationship studies improved the potency 800-fold over that of the screening leads, providing diprovocim-1 and diprovocim-2. The diprovocims act by inducing cell-surface toll-like receptor (TLR)-2 dimerization and activation with TLR1 (TLR1/TLR2 agonist), bear no structural similarity to any known natural or synthetic TLR agonist, and are easy to prepare and synthetically modify, and selected members are active in both human and murine systems. The most potent diprovocim (3, diprovocim-1) elicits full agonist activity at extraordinarily low concentrations (EC50= 110 pM) in human THP-1 cells, being more potent than the naturally derived TLR1/TLR2 agonist Pam3CSK4 or any other known small molecule TLR agonist.

DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS

A diprovocim compound that corresponds in structure to structural Formula V is disclosed, wherein A, W, Z, R1, R2, R3 and R4 (when present) are defined within. A diprovocim compound has immune-adjuvant properties on human and mouse cells in culture and on in vivo immunization of mice. A composition containing a diprovocim and a method of using a compound are also disclosed. The immunostimulatory activity of a diprovocim compound is similar to that of LPS, to which there is no apparent structural similarity. A contemplated compound bears no structural similarity to either the TLR1/TLR2 lipoprotein agonists nor to any other synthetic TLR agonist, and is remarkably easy to prepare and synthetically modify.

A mild Boc deprotection and the importance of a free carboxylate

We report a facile and rapid removal of Boc protecting groups using microwave heating in H2O, with deprotection only requiring a free carboxylic acid group in the starting material. Unlike previous approaches, no additional reagents are required.

NOVEL PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVES

The invention is concerned with novel pyrrolidine-3,4-dicarboxamide derivatives of Formula (I) ; wherein Rl to R9 and X are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These c

Chemoenzymatic preparation of non-racemic N-Boc-pyrrolidine-3,4-dicarboxylic acid 3-ethyl esters and their 4-hydroxymethyl derivatives

For the synthesis of metalloproteinase inhibitors the (R,R)- and (S,S)-monoethyl esters of N-Boc-pyrrolidine-3,4-dicarboxylic acid were prepared as key intermediates from the trans-diester racemate by two consecutive, highly selective enzymatic reactions.